Free tool
FAERS Monitor: Ravicti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203284 or its brand name (Ravicti, Glycerol Phenylbutyrate). Reports on generic versions are filed under their own applications.
Reports
1,392
Serious
843
61% of reports
Hospitalization
624
Death reported
66
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ammonia increased207
- vomiting168
- hyperammonaemia166
- decreased appetite106
- nausea74
- headache66
- hyperammonaemic crisis64
- off label use63
- diarrhoea58
- fatigue53
- somnolence53
- weight decreased47
- malaise46
- seizure44
- lethargy40
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 9 |
| 2014 | 20 |
| 2015 | 270 |
| 2016 | 260 |
| 2017 | 102 |
| 2018 | 81 |
| 2019 | 96 |
| 2020 | 63 |
| 2021 | 29 |
| 2022 | 33 |
| 2023 | 106 |
| 2024 | 193 |
| 2025 | 43 |
| 2026 | 87 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,767 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperammonaemic crisisSignal | 64 | 22510.3 | 15349.5 | 569,897 |
| ammonia increasedSignal | 207 | 638.9 | 561.7 | 125,917 |
| hyperammonaemiaSignal | 166 | 518.7 | 448.5 | 82,451 |
| lethargySignal | 40 | 10.5 | 7.7 | 336 |
| decreased appetiteSignal | 106 | 6.9 | 5.7 | 534 |
| seizureSignal | 44 | 5.8 | 4.3 | 169 |
| vomitingSignal | 168 | 5.4 | 4.7 | 611 |
| somnolenceSignal | 53 | 4.0 | 3.1 | 116 |
| weight decreasedSignal | 47 | 2.5 | 1.9 | 43 |
| headache | 66 | 1.6 | 1.3 | 14 |
| malaise | 46 | 1.6 | 1.2 | 10 |
| nausea | 74 | 1.4 | 1.1 | 9 |
| diarrhoea | 58 | 1.4 | 1.1 | 5 |
| off label use | 63 | 1.1 | 0.9 | 0 |
| fatigue | 53 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.